Key Points
- Director Brett Brodnax bought 35,000 shares of Lumexa Imaging on May 19 at an average price of $7.25, spending about $253,750. The purchase lifted his direct holdings to 62,027 shares, a 129.5% increase in his position.
- LMRI shares were up 10.5% and opened at $8.18, though the stock remains below its 50-day average of $9.75. Over the past year, it has traded between $6.45 and $19.45.
- Analyst sentiment is mixed on Lumexa Imaging, with a consensus rating of “Moderate Buy” and an average price target of $16.00. Recent actions included Barclays cutting its target to $9.00, Raymond James upgrading to strong buy with a $23.00 target, and Weiss Ratings initiating coverage with a sell rating.
Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI - Get Free Report) Director Brett Brodnax acquired 35,000 shares of the company's stock in a transaction on Tuesday, May 19th. The stock was purchased at an average cost of $7.25 per share, for a total transaction of $253,750.00. Following the completion of the purchase, the director directly owned 62,027 shares in the company, valued at $449,695.75. This trade represents a 129.50% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Lumexa Imaging Stock Up 10.5%
LMRI stock opened at $8.18 on Friday. The stock has a fifty day moving average price of $9.75. Lumexa Imaging Holdings, Inc. has a one year low of $6.45 and a one year high of $19.45.
Analysts Set New Price Targets
LMRI has been the topic of a number of analyst reports. Barclays decreased their price target on Lumexa Imaging from $15.00 to $9.00 and set an "overweight" rating on the stock in a research note on Wednesday. Raymond James Financial raised Lumexa Imaging from an "outperform" rating to a "strong-buy" rating and set a $23.00 target price on the stock in a research note on Monday, February 9th. Finally, Weiss Ratings began coverage on shares of Lumexa Imaging in a report on Wednesday, May 13th. They set a "sell (e-)" rating for the company. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.00.
Check Out Our Latest Report on Lumexa Imaging
Hedge Funds Weigh In On Lumexa Imaging
A number of hedge funds have recently made changes to their positions in LMRI. Assetmark Inc. acquired a new position in Lumexa Imaging in the fourth quarter valued at $36,000. Strs Ohio acquired a new position in shares of Lumexa Imaging in the 1st quarter valued at about $38,000. PNC Financial Services Group Inc. purchased a new stake in shares of Lumexa Imaging during the 1st quarter worth about $63,000. State of Wyoming purchased a new position in Lumexa Imaging in the first quarter valued at approximately $91,000. Finally, Barclays PLC purchased a new position in Lumexa Imaging in the fourth quarter valued at approximately $133,000.
Lumexa Imaging Company Profile
(
Get Free Report)
We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
